Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

20123,716 citationsJournal Articlebronze Open Access

Authors

Sunil Verma · Sunnybrook Health Science Centre

David Miles · Mount Vernon Cancer Centre

Luca Gianni · Mylan (Switzerland)

Ian E. Krop · Dana-Farber Cancer Institute

Manfred Welslau · Klinikum Aschaffenburg

José Baselga · Massachusetts General Hospital

Mark D. Pegram ·

Abstract

T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. (Funded by F. Hoffmann-La Roche/Genentech; EMILIA ClinicalTrials.gov number, NCT00829166.).

Topics & Keywords

HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research Click Chemistry and Applications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 367, Issue 19, pp. 1783-1791

DOI: 10.1056/nejmoa1209124

Field-Weighted Citation Impact: 120.67